

reduction of T-lymphocyte proliferation in the mammal, and wherein the mammal is a mouse, rat, rabbit, sheep, goat, or pig.

35. (Amended) A transgenic mouse whose cells express an *Fkh^{sf}* transgene comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein expression of the *Fkh^{sf}* transgene results in reduction of T-lymphocyte proliferation in the mouse.

36. (Amended) A transgenic mouse, whose cells express an *Fkh^{sf}* transgene comprising a nucleic acid molecule comprising a sequence at least 90% identical to the coding region of SEQ ID NO:1, wherein the expression of said *Fkh^{sf}* transgene results in reduction of T-Lymphocyte proliferation in said mouse.

37. (Amended) The transgenic mouse of either claim 35 or claim 36, wherein the expression of said *Fkh^{sf}* transgene results in normal size of said mouse.

38. (Amended) The transgenic mouse of either claim 35 or claim 36, wherein the expression of said *Fkh^{sf}* transgene results in normal weight of said mouse.

39. (Amended) The transgenic mouse of either claim 35 or claim 36, wherein the expression of said *Fkh^{sf}* transgene results in normal skin appearance of said mouse.

40. (Amended) The transgenic mouse of either claim 35 or claim 36, wherein the expression of said *Fkh^{sf}* transgene results in a reduction in number of lymphoid cells in a lymph node.

41. (Amended) The transgenic mouse of either claim 35 or claim 36, wherein the expression of said *Fkh^{sf}* transgene results in reduction in T-Lymphocyte responsiveness to cytokines.

42. (Amended) The transgenic mouse of either claim 35 or claim 36, wherein the expression of said *Fkh^{sf}* transgene results in reduction in T-Lymphocyte responsiveness to stimulation through cell surface receptors.